"Mevalonic Acid" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A dihydroxy monocarboxylic acid and precursor in the biosynthetic pathway known as the mevalonate pathway, which produces terpenes and steroids that are vital for diverse cellular functions.
| Descriptor ID |
D008798
|
| MeSH Number(s) |
D02.241.511.579
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Mevalonic Acid".
Below are MeSH descriptors whose meaning is more specific than "Mevalonic Acid".
This graph shows the total number of publications written about "Mevalonic Acid" by people in this website by year, and whether "Mevalonic Acid" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2019 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Mevalonic Acid" by people in Profiles.
-
Targeting the Mevalonate Pathway to Overcome Acquired Anti-HER2 Treatment Resistance in Breast Cancer. Mol Cancer Res. 2019 11; 17(11):2318-2330.
-
Caenorhabditis elegans pathways that surveil and defend mitochondria. Nature. 2014 Apr 17; 508(7496):406-10.
-
Sodium phenylbutyrate controls neuroinflammatory and antioxidant activities and protects dopaminergic neurons in mouse models of Parkinson's disease. PLoS One. 2012; 7(6):e38113.
-
Strategies to enhance epidermal growth factor inhibition: targeting the mevalonate pathway. Clin Cancer Res. 2006 Jul 15; 12(14 Pt 2):4426s-4431s.
-
HMG-CoA reductase inhibitor simvastatin mitigates VEGF-induced "inside-out" signaling to extracellular matrix by preventing RhoA activation. Am J Physiol Renal Physiol. 2006 Nov; 291(5):F995-1004.
-
Inhibitory effects of fluvastatin on cytokine and chemokine production by peripheral blood mononuclear cells in patients with allergic asthma. Clin Exp Allergy. 2006 Apr; 36(4):475-82.
-
HMG CoA reductase inhibition modulates VEGF-induced endothelial cell hyperpermeability by preventing RhoA activation and myosin regulatory light chain phosphorylation. FASEB J. 2005 Nov; 19(13):1845-7.
-
Modulatory effects of HMG-CoA reductase inhibitors in diabetic microangiopathy. FASEB J. 2004 May; 18(7):805-15.
-
Immunomodulatory effects of HMG-CoA reductase inhibitors. Arch Immunol Ther Exp (Warsz). 2003; 51(3):139-48.